multiepitope TARP-pulsed autologous dendritic cell vaccine

N/A

Report date: 2022/02/11 13:23:10

Base Information

Drug Namemultiepitope TARP-pulsed autologous dendritic cell vaccine
Drug Alias Namemulti-epitope TARP peptide-pulsed autologous dendritic cell vaccineME T-cell receptor gamma alternate reading frame protein peptide-pulsed autologous DC vaccineMulti-Epitope (ME) TARP VaccineME TARP Vaccinemulti-epitope TARP-pulsed autologous DC vaccine
ClassificationVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer Institute
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A